Abstract
Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Current Molecular Medicine
Title:Vagus nerve stimulation in treating depression: A tale of two stories.
Volume: 16 Issue: 1
Author(s): T.-F. Yuan, A. Li, X. Sun, O. Arias-Carrión and S. Machado
Affiliation:
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Abstract: Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Export Options
About this article
Cite this article as:
Yuan T.-F., Li A., Sun X., Arias-Carrión O. and Machado S., Vagus nerve stimulation in treating depression: A tale of two stories., Current Molecular Medicine 2016; 16 (1) . https://dx.doi.org/10.2174/1566524016666151222143609
DOI https://dx.doi.org/10.2174/1566524016666151222143609 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Current Pharmaceutical Design Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets Systematic Comparison of the Performance of Different 2D and 3D Ligand-Based Virtual Screening Methodologies to Discover Anticonvulsant Drugs
Combinatorial Chemistry & High Throughput Screening The Progress of Epilepsy after Stroke
Current Neuropharmacology Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Editorial [Hot Topic: Ion Channels as Therapeutic Targets for Neuropathic Pain (Executive Editor: Char-Chang Shieh)]
Current Pharmaceutical Design Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging The Effect of Mianserin on Lifespan of <i>Caenorhabditis elegan</i> is Abolished by Glucose
Current Aging Science Population Pharmacokinetics of Levetiracetam: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Current Psychopharmacology HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Conotoxin Superfamily Prediction Using Diffusion Maps Dimensionality Reduction and Subspace Classifier
Current Protein & Peptide Science Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews